Sagami Gomu Kogyo Co., Ltd. FY2026 Analysis: Guidance Points to Accelerating Growth
Sagami Gomu Kogyo Co., Ltd. (TSE:5194), a key manufacturer specializing in latex condoms and diversified into items like office and food packaging films, reported solid revenue growth for the full fiscal year ending March 2026. While the company achieved a notable turnaround in its core operating profitability, the final Net Profit saw a significant year-over-year decline, prompting a detailed analysis of the underlying profit structure.
| Metric | Current Period (JPY Mn) | Prior Period (JPY Mn) | YoY Change |
|---|---|---|---|
| Revenue | 5,911 | 5,687 | +3.9% |
| Operating Profit | 180 | -33 | N/A |
| Ordinary Income | 587 | 522 | +12.4% |
| Net Profit | 283 | 392 | -27.8% |
The company’s core business revolves around the production of latex condoms, supplemented by a diversified portfolio including films for office and food packaging. With manufacturing operations in Malaysia and significant exports across China and Asia, Sagami Gomu Kogyo Co., Ltd. maintains a stable, geographically diverse operational base.
The financial results indicate a clear divergence between operational performance and bottom-line results. Revenue increased by 3.9% YoY, confirming stable demand across its product lines. Critically, the Operating Profit successfully transitioned from a loss of -33 JPY Mn in the prior period to a positive 180 JPY Mn, signaling a strong recovery in the profitability of its core business operations. However, the Net Profit fell by 27.8% YoY to 283 JPY Mn, despite Ordinary Income rising by 12.4% YoY to 587 JPY Mn. This substantial gap between Ordinary Income and Net Profit suggests that non-operating items, such as special losses or tax adjustments, exerted a material downward influence on the final Net Profit figure.
Next Year Guidance
| Metric | Forecast (JPY Mn) | Vs. Current FY Actual |
|---|---|---|
| Revenue | 6,400 | +8.3% |
| Operating Profit | 380 | +112.8% |
| Ordinary Income | 250 | -57.3% |
| Net Profit | 60 | -78.7% |
Management’s guidance targets continued revenue growth (+8.3%) and a near-doubling of Operating Profit (+112.8%), reflecting confidence in the recovery of core manufacturing profitability. However, Ordinary Income and Net Profit are forecast to decline sharply year-over-year, likely reflecting the unwinding of non-recurring gains that inflated these metrics in FY2026.
Key Observations for International Investors
The most salient point for international investors is the divergence between FY2026 results and the FY2027 outlook. While FY2026 Ordinary Income rose to ¥587mn (+12.4%) and Net Profit was ¥283mn, the guidance for FY2027 calls for sharp declines in both metrics (Ordinary Income ¥250mn, Net Profit ¥60mn). This implies that FY2026 benefited from non-recurring income items that will not repeat. In contrast, Operating Profit is guided to nearly double to ¥380mn (+112.8%), signaling genuine improvement in manufacturing profitability.
Furthermore, the company’s financial structure remains highly robust, evidenced by the Equity Ratio holding at 60.6%, indicating a strong balance sheet with low reliance on debt financing. The consistent increase in Revenue, supported by its international footprint, underscores the success of its market penetration strategies, particularly within the healthcare segment and expanding cross-border e-commerce channels.
Moving forward, investors should monitor the composition of non-recurring income that boosted Ordinary Income and Net Profit in FY2026, as management does not expect these to recur in FY2027. The key indicator to watch is Operating Profit, where the company targets ¥380mn — a level that, if achieved, would represent genuine structural improvement. The diversified strategy spanning the condom segment, film applications, and cross-border e-commerce remains the foundation for long-term revenue growth toward the ¥6.4bn target.
Source: Original filing (TDnet) | 日本語版
This article is for informational purposes only and does not constitute investment advice. Financial figures are AI-extracted and may contain errors — always verify against the original filing.